Novo Nordisk disputes Pfizer's attempt to end US HRT agreement

Published: 2-Jun-2003

Danish company Novo Nordisk claims Pfizer has attempted to terminate the license agreement under which Pfizer markets Novo Nordisk\'s portfolio of hormone replacement therapy products in the US.


Danish company Novo Nordisk claims Pfizer has attempted to terminate the license agreement under which Pfizer markets Novo Nordisk's portfolio of hormone replacement therapy products in the US.

The company is contesting Pfizer's ability to terminate the agreement, which covers the currently marketed products Activella and Vagifem.

Executive vice president and chief operating officer Kare Schultz said: 'We are surprised and disappointed by Pfizer's reduction in promotional support of these products and by their attempt to terminate the agreement. We do not believe that Pfizer has a contractual right to terminate the entire agreement and Novo Nordisk is working towards safeguarding its interests following the unexpected and early termination of the agreement.'

Novo Nordisk is currently evaluating various alternatives for continuing the marketing of HRT portfolio in the US; the products will remain available as usual, it says.

Trending Articles

You may also like